We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Method Extends Range of Bacteriophage-based Applications

By LabMedica International staff writers
Posted on 04 Jul 2017
A team of Israeli molecular microbiologists developed a method for extending the host specificity of bacteriophage particles to enable them to transfer DNA into a wide range of pathogenic bacteria.

A major limitation in using bacteriophage-based applications is their narrow host range. More...
Approaches for extending the host range have focused primarily on lytic phages in hosts supporting their propagation rather than approaches for extending the ability of DNA transduction into phage-restrictive hosts.

To extend the host range of T7 phage for DNA transduction, investigators at Tel Aviv University (Israel) designed a novel class of hybrid particles that displayed various bacteriophage tail/tail fiber protein combinations. The investigators programmed these modular particles to package and transduce DNA into hosts that normally restricted T7 phage propagation.

The investigators also developed an innovative generalizable platform that considerably enhanced DNA transfer into new hosts by artificially selecting tails that efficiently transduced DNA. In addition, they demonstrated that the hybrid particles were able to transduce desired DNA into desired hosts.

"DNA manipulation of pathogens includes sensitization to antibiotics, killing of pathogens, disabling pathogens' virulence factors, and more," said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. "We have developed a technology that significantly expands DNA delivery into bacterial pathogens. This may indeed be a milestone, because it opens up many opportunities for DNA manipulations of bacteria that were impossible to accomplish before. This could pave the way to changing the human microbiome - the combined genetic material of the microorganisms in humans - by replacing virulent bacteria with a-virulent bacteria and replacing antibiotic-resistant bacteria with antibiotic-sensitive bacteria, as well as changing environmental pathogens. We have applied for a patent on this technology and are developing products that would use this technology to deliver DNA into bacterial pathogens, rendering them a-virulent and sensitive to antibiotics."

The bacteriophage study was published in the June 1, 2017, issue of the journal Molecular Cell.

Related Links:
Tel Aviv University


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.